Current staging of renal cell carcinoma

Bradley C. Leibovich, Allan J. Pantuck, Matthew H.T. Bui, Ken Ryu-Han, Amnon Zisman, Robert Figlin, Arie Belldegrun

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Most (>80%) cancers involving the kidney are renal cell carcinoma (RCC). One third of patients diagnosed with kidney cancer have evidence of metastatic disease at the time of diagnosis, and as many as half of patients treated for localized disease eventually relapse. As is true for any other malignancy, one must determine which tumor features, patient factors, and laboratory techniques will provide diagnostic and prognostic information for patients with RCC. This article focuses on the history and rationale of the current staging systems for RCC as well as the potential for improvements by the addition of other clinical, pathologic, and molecular prognostic markers.

Original languageEnglish (US)
Pages (from-to)481-497
Number of pages17
JournalUrologic Clinics of North America
Volume30
Issue number3
DOIs
StatePublished - Aug 2003

Fingerprint

Renal Cell Carcinoma
Kidney Neoplasms
Neoplasms
History
Recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Leibovich, B. C., Pantuck, A. J., Bui, M. H. T., Ryu-Han, K., Zisman, A., Figlin, R., & Belldegrun, A. (2003). Current staging of renal cell carcinoma. Urologic Clinics of North America, 30(3), 481-497. https://doi.org/10.1016/S0094-0143(03)00029-6

Current staging of renal cell carcinoma. / Leibovich, Bradley C.; Pantuck, Allan J.; Bui, Matthew H.T.; Ryu-Han, Ken; Zisman, Amnon; Figlin, Robert; Belldegrun, Arie.

In: Urologic Clinics of North America, Vol. 30, No. 3, 08.2003, p. 481-497.

Research output: Contribution to journalReview article

Leibovich, BC, Pantuck, AJ, Bui, MHT, Ryu-Han, K, Zisman, A, Figlin, R & Belldegrun, A 2003, 'Current staging of renal cell carcinoma', Urologic Clinics of North America, vol. 30, no. 3, pp. 481-497. https://doi.org/10.1016/S0094-0143(03)00029-6
Leibovich BC, Pantuck AJ, Bui MHT, Ryu-Han K, Zisman A, Figlin R et al. Current staging of renal cell carcinoma. Urologic Clinics of North America. 2003 Aug;30(3):481-497. https://doi.org/10.1016/S0094-0143(03)00029-6
Leibovich, Bradley C. ; Pantuck, Allan J. ; Bui, Matthew H.T. ; Ryu-Han, Ken ; Zisman, Amnon ; Figlin, Robert ; Belldegrun, Arie. / Current staging of renal cell carcinoma. In: Urologic Clinics of North America. 2003 ; Vol. 30, No. 3. pp. 481-497.
@article{5cd44c027ea84b2881117e5bd99c6ee9,
title = "Current staging of renal cell carcinoma",
abstract = "Most (>80{\%}) cancers involving the kidney are renal cell carcinoma (RCC). One third of patients diagnosed with kidney cancer have evidence of metastatic disease at the time of diagnosis, and as many as half of patients treated for localized disease eventually relapse. As is true for any other malignancy, one must determine which tumor features, patient factors, and laboratory techniques will provide diagnostic and prognostic information for patients with RCC. This article focuses on the history and rationale of the current staging systems for RCC as well as the potential for improvements by the addition of other clinical, pathologic, and molecular prognostic markers.",
author = "Leibovich, {Bradley C.} and Pantuck, {Allan J.} and Bui, {Matthew H.T.} and Ken Ryu-Han and Amnon Zisman and Robert Figlin and Arie Belldegrun",
year = "2003",
month = "8",
doi = "10.1016/S0094-0143(03)00029-6",
language = "English (US)",
volume = "30",
pages = "481--497",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Current staging of renal cell carcinoma

AU - Leibovich, Bradley C.

AU - Pantuck, Allan J.

AU - Bui, Matthew H.T.

AU - Ryu-Han, Ken

AU - Zisman, Amnon

AU - Figlin, Robert

AU - Belldegrun, Arie

PY - 2003/8

Y1 - 2003/8

N2 - Most (>80%) cancers involving the kidney are renal cell carcinoma (RCC). One third of patients diagnosed with kidney cancer have evidence of metastatic disease at the time of diagnosis, and as many as half of patients treated for localized disease eventually relapse. As is true for any other malignancy, one must determine which tumor features, patient factors, and laboratory techniques will provide diagnostic and prognostic information for patients with RCC. This article focuses on the history and rationale of the current staging systems for RCC as well as the potential for improvements by the addition of other clinical, pathologic, and molecular prognostic markers.

AB - Most (>80%) cancers involving the kidney are renal cell carcinoma (RCC). One third of patients diagnosed with kidney cancer have evidence of metastatic disease at the time of diagnosis, and as many as half of patients treated for localized disease eventually relapse. As is true for any other malignancy, one must determine which tumor features, patient factors, and laboratory techniques will provide diagnostic and prognostic information for patients with RCC. This article focuses on the history and rationale of the current staging systems for RCC as well as the potential for improvements by the addition of other clinical, pathologic, and molecular prognostic markers.

UR - http://www.scopus.com/inward/record.url?scp=0042821697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042821697&partnerID=8YFLogxK

U2 - 10.1016/S0094-0143(03)00029-6

DO - 10.1016/S0094-0143(03)00029-6

M3 - Review article

C2 - 12953750

AN - SCOPUS:0042821697

VL - 30

SP - 481

EP - 497

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 3

ER -